Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




Nov
11
Today In Oncology
CTCL Denileukin Diftitox May Improve HRQoL
Researchers Pinpoint Hundreds of Genetic Variants That May Offer New Insights Into Inherited Breast Cancer Risk
Anbenitamab/HB1801 vs THP in HER2-Positive Advanced Breast Cancer
KEYNOTE-867 Immunotherapy Should Not Be Combined With SBRT in Unresected Early-Stage NSCLC
FDA Approves Pimicotinib for Symptomatic TGCT
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo